kevin kalinsky, md, summarizes recent clinical data regarding the role of cdk 4/6 inhibitors
Published 3 years ago • 109 plays • Length 2:48
Download video MP4
Download video MP3
Similar videos
-
17:54
expert perspectives: cdk 4/6 inhibitors for er breast cancer: current data and clinical use
-
1:06
priya rastogi, md, considers the interchangeability of cdk 4/6 inhibitors
-
21:11
current clinical data for cdk 4/6 inhibitors in breast cancer
-
1:57
kevin kalinsky, md, regarding ctcs as a predictor of overall survival in metastatic breast cancer
-
9:42
expert perspectives: rationale for cdk 4/6 inhibition in breast cancer
-
15:06
mechanistic activity and development history of cdk 4/6 inhibitors
-
7:47
the cell cycle - part 2: cyclins, cyclin dependent kinases (cdks), cdk inhibitors
-
6:16
cyclins and cdks cell cycle regulation
-
11:26
cell cycle regulation, part 6: cdki regulation
-
13:05
expert perspectives: cdk 4/6 inhibitor therapy for er metastatic breast cancer
-
0:45
nancy lin, md, explores the role of cdk4/6 inhibitors in metastatic breast cancer management
-
7:58
cdk 4/6 inhibitors: how are they used in metastatic breast cancer treatment?
-
41:49
winship grand rounds: april 13, 2022 - kevin kalinsky, md, ms
-
2:22
kevin kalinsky, md, shares impressions of the rxponder clinical trial presented at sabcs 2020
-
7:59
what are cdk 4/6 inhibitors for breast cancer?
-
0:29
kevin kalinsky, md | winship cancer institute of emory university
-
4:50
hope rugo, md, provides perspective on the clinical progress of cdk 4/6 inhibitors in breast cancer
-
5:16
the clinical potential of cdk4/6 inhibitors
-
8:55
cdk4/6 inhibitors in hr metastatic breast cancer
-
7:40
cdk4/6 inhibitors in the first-line treatment setting
-
4:54
monarch 3 study: cdk4/6 inhibitors in the treatment of metastatic breast cancer
-
1:20
dr. finn on new cdk 4/6 inhibitors for breast cancer
Clip.africa.com - Privacy-policy